In conclusion, various findings have found that the activation of FoxO3a and its downstream genes are of clinical importance in diverse anticancer therapeutics, including in CML treatment. The gene discussed is FOXO3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.